Obesity and polycystic ovary syndrome

The aetiology of Polycystic Ovary Syndrome (PCOS) is complex and multifactorial. There is much evidence, however, to suggest that adipose tissue plays an important role in the development and maintenance of PCOS pathology. There is a close correlation between adiposity and symptom severity in women with PCOS, and even modest reductions in weight generally translate into significant improvements in menstrual regularity, fertility and hyperandrogenic features. This review article considers the various mechanisms that might underlie this link between excess adiposity and PCOS – including the effects of differential insulin sensitivity, abnormal steroid hormone metabolism and adipocytokine secretion. Greater attention to the therapeutic options available to reduce the impact of excess adiposity on ovarian and metabolic function is essential to the management of PCOS.

[1]  B. Knebel,et al.  The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome , 2005, Clinical endocrinology.

[2]  A. Kitabchi,et al.  Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. , 1980, The Journal of clinical endocrinology and metabolism.

[3]  L. Wide,et al.  The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women , 1994, Clinical endocrinology.

[4]  G. Stewart.  Safety of pertussis vaccine , 1990, The Lancet.

[5]  J. Olefsky,et al.  Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  Johannes D. Veldhuis,et al.  Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Zborowski,et al.  Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. , 2002, Fertility and sterility.

[8]  Matej Oresic,et al.  The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. , 2005, Diabetes.

[9]  N. Sattar,et al.  Circulating leptin concentrations and ovarian function in polycystic ovary syndrome. , 2001, European journal of endocrinology.

[10]  D. Rosenbaum,et al.  Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. , 1993, The American journal of physiology.

[11]  H. Escobar-Morreale,et al.  High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[12]  M. Tschöp,et al.  Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  L. Levitsky,et al.  Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. , 1994, The Journal of clinical endocrinology and metabolism.

[14]  T. Tsilchorozidou,et al.  Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  R. Vettor,et al.  Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. , 1998, Metabolism: clinical and experimental.

[16]  I. Vauhkonen,et al.  Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. , 2000, Human reproduction.

[17]  M. Tschöp,et al.  Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome , 2003, Journal of endocrinological investigation.

[18]  D. Magoffin,et al.  Direct Intraovarian Effects of Leptin: Impairment of the Synergistic Action of Insulin-Like Growth Factor-I on Follicle-Stimulating Hormone-Dependent Estradiol-17β Production by Rat Ovarian Granulosa Cells. , 1997, Endocrinology.

[19]  H. Mason,et al.  Mechanisms of anovulation in polycystic ovary syndrome , 1997 .

[20]  D. McMahon,et al.  Increased 5α-Reductase and Normal 11β-Hydroxysteroid Dehydrogenase Metabolism of C19 and C21 Steroids in a Young Population with Polycystic Ovarian Syndrome , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[21]  R. Legro.  The Genetics of Obesity Lessons for Polycystic Ovary Syndrome , 2000, Annals of the New York Academy of Sciences.

[22]  G. Kaltsas,et al.  Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. , 1995, Human reproduction.

[23]  J. L. San Millán,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain* , 1999 .

[24]  M. Fassnacht,et al.  Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5??-reductase Activity in Women With Polycystic Ovary Syndrome , 2003 .

[25]  P. Arner,et al.  A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. , 2002, Diabetes.

[26]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[27]  S. Agarwal,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Leptin Antagonizes the Insulin-Like Growth Factor-I Augmentation of Steroidogenesis in Granulosa and , 2022 .

[28]  J. Sowiński,et al.  Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[30]  S. Kirchengast,et al.  Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. , 2001, Human reproduction.

[31]  R. Pasquali,et al.  Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. , 1989, The Journal of clinical endocrinology and metabolism.

[32]  B. Çakır,et al.  Insulin Resistance in Nonobese Patients with Polycystic Ovary Syndrome , 2001, Hormone Research in Paediatrics.

[33]  A. Belgorosky,et al.  Hypothalamic-pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  M. Laakso,et al.  Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. , 2003, Human reproduction.

[35]  J. Rood,et al.  Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[36]  D. Dunger,et al.  Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. , 2005, Human reproduction.

[37]  S. Franks,et al.  Developmental origin of polycystic ovary syndrome - a hypothesis. , 2002, The Journal of endocrinology.

[38]  J. Seidell,et al.  Long-term testosterone administration increases visceral fat in female to male transsexuals. , 1997, The Journal of clinical endocrinology and metabolism.

[39]  D. Ehrmann,et al.  Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  R. Jennrich,et al.  - Cell Function : A Key Pathological Determinant in Polycystic Ovary Syndrome , 2004 .

[41]  A. Boulton,et al.  Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity. , 1999, The Journal of clinical endocrinology and metabolism.

[42]  C. Schöfl,et al.  Circulating ghrelin levels in patients with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[43]  E. Simpson.  Sources of estrogen and their importance , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  P. Björntorp,et al.  The effects of androgens on the regulation of lipolysis in adipose precursor cells. , 1990, Endocrinology.

[45]  J. Clore,et al.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[46]  C. Edwards,et al.  5 alpha-reductase activity in polycystic ovary syndrome. , 1990, Lancet.

[47]  M. McCarthy,et al.  Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. , 1997, Human molecular genetics.

[48]  K. Seow,et al.  Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. , 2004, Human reproduction.

[49]  C. Berne,et al.  Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. , 1995, The Journal of clinical endocrinology and metabolism.

[50]  D. Cibula,et al.  Is insulin resistance an essential component of PCOS?: The influence of confounding factors. , 2004, Human reproduction.

[51]  S. Rice,et al.  Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. , 2005, Human reproduction.

[52]  A. Balen.  The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. , 1995, Human reproduction.

[53]  A. Balen,et al.  Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? , 2002, Clinical endocrinology.

[54]  B. Walker,et al.  Obesity and gender influence cortisol secretion and metabolism in man. , 1998, The Journal of clinical endocrinology and metabolism.

[55]  P. Björntorp,et al.  Effect of testosterone on abdominal adipose tissue in men. , 1991, International journal of obesity.

[56]  S. Franks,et al.  Gonadotrophin and gonadal steroid response to a single dose of a long‐acting agonist of gonadotrophin‐releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome , 1995, Clinical endocrinology.

[57]  M. McCarthy,et al.  Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. , 2003, The Journal of clinical endocrinology and metabolism.

[58]  E. Adashi,et al.  Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. , 1981, Endocrinology.

[59]  M. Noakes,et al.  Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. , 2004, The Journal of clinical endocrinology and metabolism.

[60]  H. Yki-Järvinen,et al.  Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[61]  R. Pasquali,et al.  The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women , 1991, Journal of endocrinological investigation.

[62]  E Tafeit,et al.  Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. , 2004, American journal of physical anthropology.

[63]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[64]  A. Barnett,et al.  11β-Hydroxysteroid dehydrogenase Type 1 activity in lean and obese males with Type 2 diabetes mellitus , 2004 .

[65]  M. Quinkler,et al.  Androgen generation in adipose tissue in women with simple obesity--a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. , 2004, The Journal of endocrinology.

[66]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[67]  A. Venkatesan,et al.  Insulin resistance in polycystic ovary syndrome: progress and paradoxes. , 2001, Recent progress in hormone research.

[68]  J. Strauss,et al.  Insulin as an effector of human ovarian and adrenal steroid metabolism. , 1991, Endocrinology and metabolism clinics of North America.

[69]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[70]  C. Berne,et al.  Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. , 1994, The Journal of clinical endocrinology and metabolism.

[71]  Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[72]  Jimmy D Bell,et al.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.

[73]  S. Franks.  The ubiquitous polycystic ovary. , 1991, The Journal of endocrinology.

[74]  P. McKeigue,et al.  Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study , 2000, Clinical endocrinology.

[75]  C. Edwards,et al.  5 α-reductase activity in polycystic ovary syndrome , 1990, The Lancet.

[76]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[77]  R. Clayton,et al.  Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. , 1994, The New England journal of medicine.

[78]  D. Johnston,et al.  The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries , 1993, Clinical endocrinology.

[79]  H. Mason,et al.  Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. , 1998, The Journal of clinical endocrinology and metabolism.

[80]  S. Franks,et al.  Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. , 1992, Clinical endocrinology.

[81]  U. Meinhardt,et al.  The Aromatase Cytochrome P-450 and Its Clinical Impact , 2002, Hormone Research in Paediatrics.

[82]  N. Cox,et al.  Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. , 2002, The Journal of clinical endocrinology and metabolism.